Search Results - "BESSARD, Anne"

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m 2 ) and the Currently Approved Dose (25 mg/m 2 ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA by Eisenberger, Mario, Hardy-Bessard, Anne-Claire, Kim, Choung Soo, Géczi, Lajos, Ford, Daniel, Mourey, Loïc, Carles, Joan, Parente, Phillip, Font, Albert, Kacso, Gabriel, Chadjaa, Mustapha, Zhang, Wenping, Bernard, John, de Bono, Johann

“…Purpose Cabazitaxel 25 mg/m (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic…”
Get full text

Effective treatment based on monitoring bESR1 mutations – Authors' reply by Bidard, Francois-Clément, Hardy-Bessard, Anne-Claire, Delaloge, Suzette

Get full text

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial by Harter, Philipp, Mouret-Reynier, Marie Ange, Pignata, Sandro, Cropet, Claire, González-Martín, Antonio, Bogner, Gerhard, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Nøttrup, Trine Jakobi, Floquet, Anne, El-Balat, Ahmed, Scambia, Giovanni, Guerra Alia, Eva Maria, Fabbro, Michel, Schmalfeldt, Barbara, Hardy-Bessard, Anne-Claire, Runnebaum, Ingo, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle

“…Adding maintenance olaparib to bevacizumab provided a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian…”
Get full text

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer by O'Malley, David M., Oaknin, Ana, Monk, Bradley J., Selle, Frédéric, Rojas, Carlos, Gladieff, Laurence, Berton, Dominique, Leary, Alexandra, Moore, Kathleen N., Estevez-Diz, Maria D.P., Hardy-Bessard, Anne-Claire, Alexandre, Jérôme, Opperman, Christina P., de Azevedo, Carla Rameri A.S., Randall, Leslie M., Feliu, Waldo Ortuzar, Ancukiewicz, Marek, Ray-Coquard, Isabelle

“…This phase II clinical trial evaluated the safety and antitumor activity of balstilimab, an anti-PD-1 antibody, in patients with previously-treated,…”
Get full text

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study by Abida, Wassim, Campbell, David, Patnaik, Akash, Bryce, Alan H., Shapiro, Jeremy, Bambury, Richard M., Zhang, Jingsong, Burke, John M., Castellano, Daniel, Font, Albert, Ganju, Vinod, Hardy-Bessard, Anne-Claire, McDermott, Ray, Sautois, Brieuc, Spaeth, Dominique, Voog, Eric, Piulats, Josep M., Pintus, Elias, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Loehr, Andrea, Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Go, Jowell, Watkins, Simon P., Chowdhury, Simon

“…Final results of the TRITON2 study of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene alterations confirm the…”
Get full text

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer by Bachelot, Thomas, Cottu, Paul, Chabaud, Sylvie, Dalenc, Florence, Allouache, Djelila, Delaloge, Suzette, Jacquin, Jean-Philippe, Grenier, Julien, Venat Bouvet, Laurence, Jegannathen, Apurna, Campone, Mario, Del Piano, Francesco, Debled, Marc, Hardy-Bessard, Anne-Claire, Giacchetti, Sylvie, Mouret-Reynier, Marie-Ange, Barthelemy, Philippe, Kaluzinski, Laure, Mailliez, Audrey, Legouffe, Eric, Sephton, Matthew, Bliss, Judith, Canon, Jean-Luc, Penault-Llorca, Frederique, Lemonnier, Jerome, Cameron, David, Andre, Fabrice

“…Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in…”
Get full text

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial by Giacchetti, Sylvie, Laas, Enora, Bachelot, Thomas, Lemonnier, Jérome, André, Fabrice, Cameron, David, Bliss, Judith, Chabaud, Sylvie, Hardy- Bessard, Anne-Claire, Lacroix-Triki, Magali, Canon, Jean-Luc, Debled, Marc, Campone, Mario, Cottu, Paul, Dalenc, Florence, Ballesta, Annabelle, Penault-Llorca, Frederique, Asselain, Bernard, Dumas, Elise, Reyal, Fabien, Gougis, Paul, Lévi, Francis, Hamy, Anne-Sophie

“…Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this…”
Get full text

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial by Spielmann, Marc, Roché, Henri, Delozier, Thierry, Canon, Jean-Luc, Romieu, Gilles, Bourgeois, Hugues, Extra, Jean-Marc, Serin, Daniel, Kerbrat, Pierre, Machiels, Jean-Pascal, Lortholary, Alain, Orfeuvre, Hubert, Campone, Mario, Hardy-Bessard, Anne-Claire, Coudert, Bruno, Maerevoet, Marie, Piot, Gilles, Kramar, Andrew, Martin, Anne-Laure, Penault-Llorca, Frédérique

“…To evaluate the efficacy of trastuzumab in patients with node-positive breast cancer treated with surgery, adjuvant chemotherapy, radiotherapy, and hormone…”
Get full text

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study by Ferrero, Jean‐Marc, Hardy‐Bessard, Anne‐Claire, Capitain, Olivier, Lortholary, Alain, Salles, Bruno, Follana, Philippe, Herve, Robert, Deblock, Mathilde, Dauba, Jérôme, Atlassi, Mustapha, Largillier, Rémy

“…BACKGROUND The current study was performed to determine the efficacy and safety of first‐line combination therapy with bevacizumab, paclitaxel, and…”
Get full text

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study by Bertucci, François, Prof, Fekih, Mahmoud, MD, Autret, Aurélie, MSc, Petit, Thierry, Prof, Dalenc, Florence, MD, Levy, Christelle, MD, Romieu, Gilles, MD, Bonneterre, Jacques, Prof, Ferrero, Jean-Marc, Prof, Kerbrat, Pierre, Prof, Soulie, Patrick, MD, Mouret-Reynier, Marie-Ange, MD, Bachelot, Thomas, MD, Lerebours, Florence, MD, Eymard, Jean-Christophe, MD, Deblock, Mathilde, MD, Lortholary, Alain, MD, Hardy-Bessard, Anne-Claire, MD, Barthelemy, Philippe, MD, Bonnefoi, Hervé, Prof, Charafe-Jauffret, Emmanuelle, Prof, Bidard, François-Clément, MD, Viens, Patrice, Prof, Lemonnier, Jérôme, PhD, Pierga, Jean-Yves, Prof

“…Summary Background Addition of bevacizumab to standard chemotherapy in the neoadjuvant setting in patients with HER2-negative metastatic breast cancer improves…”
Get full text

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial by Matulonis, Ursula A, Walder, Lydia, Nøttrup, Trine J, Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A, Wenham, Robert M, Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, Mirza, Mansoor R

“…This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients…”
Get full text

GLP-2 Prevents Neuronal and Glial Changes in the Distal Colon of Mice Chronically Treated with Cisplatin by Nardini, Patrizia, Pini, Alessandro, Bessard, Anne, Duchalais, Emilie, Niccolai, Elena, Neunlist, Michel, Vannucchi, Maria Giuliana

“…Cisplatin is a chemotherapeutic agent widely used for the treatment of solid cancers. Its administration is commonly associated with acute and chronic…”
Get full text

Region-specific remodeling of the enteric nervous system and enteroendocrine cells in the colon of spinal cord injury patients by Lefèvre, Chloë, Le Roy, Camille, Bessard, Anne, Le Berre-Scoul, Catherine, Marchix, Justine, Coron, Emmanuel, Le Rhun, Marc, Brochard, Charlène, Perrouin-Verbe, Brigitte, Neunlist, Michel

“…Patients with spinal cord injury (SCI) suffer from major bowel dysfunction, whose exact pathophysiology, particularly the involvement of the enteric nervous…”
Get full text

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy by Lee, Chee Khoon, Asher, Rebecca, Friedlander, Michael, Gebski, Val, Gonzalez-Martin, Antonio, Lortholary, Alain, Lesoin, Anne, Kurzeder, Christian, Largillier, Remy, Hilpert, Felix, Hardy-Bessard, Anne-Claire, Kaminsky, Marie-Christine, Poveda, Andres, Pujade-Lauraine, Eric

“…Platinum-resistant ovarian cancer (PROC) is associated with a variable prognosis and unpredictable survival times. We have developed and validated a prognostic…”
Get full text

Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy by Lequesne, Justine, Joly, Florence, Peron, Julien, Ray-Coquard, Isabelle, Hardy-Bessard, Anne-Claire, Selle, Frédéric, Berton, Dominique, Follana, Philippe, Fabbro, Michel, Lortholary, Alain, Pujade-Lauraine, Eric, Lefèvre-Arbogast, Sophie, Coquan, Elodie

“…Current standards for toxicity reporting do not fully capture the impact of adverse events (AEs) on patients' quality of life (QoL). This study aimed to…”
Get more information

Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA‑1 Trial: Feasibility and Cross-Validation with NGS by Callens, Celine, Bidard, Francois-Clement, Curto-Taribo, Anaïs, Trabelsi-Grati, Olfa, Melaabi, Samia, Delaloge, Suzette, Hardy-Bessard, Anne-Claire, Bachelot, Thomas, Clatot, Florian, De La Motte Rouge, Thibault, Canon, Jean-Luc, Arnould, Laurent, Andre, Fabrice, Marques, Sandrine, Stern, Marc-Henri, Pierga, Jean-Yves, Vincent-Salomon, Anne, Benoist, Camille, Jeannot, Emmanuelle, Berger, Frederique, Bieche, Ivan, Pradines, Anne

“…The clinical actionability of circulating tumor DNA requires sensitive detection methods with a short turnaround time. In the PADA-1 phase 3 trial…”
Get full text

High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer by Bessard, Anne, Solé, Véronique, Bouchaud, Grégory, Quéméner, Agnès, Jacques, Yannick

“…Interleukin (IL)-15 has an important role in tumor immunosurveillance and has a contemplated use in tumor immunotherapy. We have previously engineered the…”
Get full text

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial by Lee, Chee Khoon, Lord, Sarah, Grunewald, Tami, Gebski, Val, Hardy-Bessard, Anne-Claire, Sehouli, Jalid, Woie, Kathrine, Heywood, Mark, Schauer, Christian, Vergote, Ignace, Scambia, Giovanni, Ferrero, Annamaria, Harter, Philipp, Pujade-Lauraine, Eric, Friedlander, Michael

“…Abstract Objective The role of secondary cytoreductive surgery (SCR) in platinum-sensitive recurrent ovarian cancer (ROC) remains controversial. The overall…”
Get full text

Fibrillar collagen scoring by second harmonic microscopy: A new tool in the assessment of liver fibrosis by Gailhouste, Luc, Grand, Yann Le, Odin, Christophe, Guyader, Dominique, Turlin, Bruno, Ezan, Frédéric, Désille, Yoann, Guilbert, Thomas, Bessard, Anne, Frémin, Christophe, Theret, Nathalie, Baffet, Georges

“…Background & Aims Imaging of supramolecular structures by multiphoton microscopy offers significant advantages for studying specific fibrillar compounds in…”
Get full text

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial by Lorusso, Domenica, Mouret-Reynier, Marie-Ange, Harter, Philipp, Cropet, Claire, Caballero, Cristina, Wolfrum-Ristau, Pia, Satoh, Toyomi, Vergote, Ignace, Parma, Gabriella, Nøttrup, Trine J, Lebreton, Coriolan, Fasching, Peter A, Pisano, Carmela, Manso, Luis, Bourgeois, Hugues, Runnebaum, Ingo, Zamagni, Claudio, Hardy-Bessard, Anne-Claire, Schnelzer, Andreas, Fabbro, Michel, Schmalfeldt, Barbara, Berton, Dominique, Belau, Antje, Lotz, Jean-Pierre, Gropp-Meier, Martina, Gladieff, Laurence, Lück, Hans-Joachim, Abadie-Lacourtoisie, Sophie, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle

“…In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients…”
Get more information